Skip to main content

Compare Stocks

Date Range: 

 ArvinasKaruna TherapeuticsPacira BioSciencesAlkermesMorphoSys
SymbolNASDAQ:ARVNNASDAQ:KRTXNASDAQ:PCRXNASDAQ:ALKSNASDAQ:MOR
Price Information
Current Price$63.84$115.73$61.46$22.24$20.34
52 Week RangeBuyBuyBuyHoldHold
MarketRank™
Overall Score1.71.82.31.20.3
Analysis Score4.54.54.31.00.0
Community Score2.43.02.92.81.4
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.01.70.0
Earnings & Valuation Score0.00.04.40.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldHold
Consensus Price Target$113.15$151.70$78.58$22.00N/A
% Upside from Price Target77.25% upside31.08% upside27.86% upside-1.08% downsideN/A
Trade Information
Market Cap$3.13 billion$3.41 billion$2.71 billion$3.57 billion$2.68 billion
Beta2.142.071.271.251.03
Average Volume452,741189,977488,7551,385,61254,646
Sales & Book Value
Annual Revenue$42.98 millionN/A$421.03 million$1.17 billion$80.43 million
Price / Sales72.76N/A6.433.0533.27
CashflowN/AN/A$1.44 per share$0.59 per shareN/A
Price / CashN/AN/A42.5637.52N/A
Book Value$6.72 per share$16.65 per share$8.51 per share$6.89 per share$3.49 per share
Price / Book9.50N/A7.223.235.83
Profitability
Net Income$-70,290,000.00$-43,960,000.00$-11,020,000.00$-196,620,000.00$-115,380,000.00
EPS($2.13)($3.68)$0.86$0.07($0.91)
Trailing P/E RatioN/AN/A21.64N/A96.86
Forward P/E RatioN/AN/A21.34317.71N/A
P/E GrowthN/AN/A0.8212.74N/A
Net Margins-403.77%N/A29.95%-6.28%8.76%
Return on Equity (ROE)-46.99%-13.91%10.71%9.35%4.51%
Return on Assets (ROA)-35.34%-13.72%4.88%5.50%2.25%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.01%N/A0.78%0.25%N/A
Current Ratio6.53%70.57%7.63%2.71%5.02%
Quick Ratio6.53%70.56%6.84%2.39%4.93%
Ownership Information
Institutional Ownership Percentage75.68%74.83%N/A97.30%3.06%
Insider Ownership Percentage10.99%18.10%5.80%4.49%N/A
Miscellaneous
Employees179636242,245615
Shares Outstanding48.99 million29.46 million44.03 million160.45 million131.56 million
Next Earnings Date8/3/2021 (Estimated)8/4/2021 (Estimated)8/5/2021 (Estimated)8/4/2021 (Estimated)8/4/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Incyte and Morphosys dose first patient in late-stage lymphoma studyIncyte and Morphosys dose first patient in late-stage lymphoma study
seekingalpha.com - May 13 at 8:54 AM
MorphoSys (NASDAQ:MOR) Issues FY 2021 Earnings GuidanceMorphoSys (NASDAQ:MOR) Issues FY 2021 Earnings Guidance
americanbankingnews.com - May 12 at 7:40 AM
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND ...MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND ...
pr-inside.com - May 11 at 7:11 PM
PRESS RELEASE: MorphoSys and Incyte Announce -3-PRESS RELEASE: MorphoSys and Incyte Announce -3-
finanztreff.de - May 11 at 7:11 PM
MorphoSys (NASDAQ:MOR) Reaches New 1-Year Low at $20.12MorphoSys (NASDAQ:MOR) Reaches New 1-Year Low at $20.12
americanbankingnews.com - May 11 at 11:39 AM
MorphoSys (NASDAQ:MOR) Shares Gap Down to $21.47MorphoSys (NASDAQ:MOR) Shares Gap Down to $21.47
americanbankingnews.com - May 10 at 3:26 PM
MorphoSys AG (MOR) CEO Jean-Paul Kress on Q1 2021 Results - Earnings Call TranscriptMorphoSys AG (MOR) CEO Jean-Paul Kress on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 7:41 AM
MorphoSys ADR Earnings, Revenue Miss in Q1MorphoSys ADR Earnings, Revenue Miss in Q1
investing.com - May 6 at 11:39 PM
Morphosys AG Earnings Miss, Revenue Beats In Q1Morphosys AG Earnings Miss, Revenue Beats In Q1
investing.com - May 6 at 11:39 PM
FIRMEN-BLICK-Morphosys rutscht im Auftaktquartal in die roten ZahlenFIRMEN-BLICK-Morphosys rutscht im Auftaktquartal in die roten Zahlen
de.investing.com - May 6 at 3:36 AM
DGAP-News MorphoSys AG berichtet über die Ergebnisse des ersten Quartals 2021 (deutsch)DGAP-News MorphoSys AG berichtet über die Ergebnisse des ersten Quartals 2021 (deutsch)
wallstreet-online.de - May 6 at 3:36 AM
Wichtige Kursbewegungen: Morphosys fallen weiter - JPM: Monjuvi-Umsatz von Incyte schwachWichtige Kursbewegungen: Morphosys fallen weiter - JPM: Monjuvi-Umsatz von Incyte schwach
boerse-online.de - May 6 at 3:36 AM
DGAP-News: MorphoSys AG berichtet über die -2-DGAP-News: MorphoSys AG berichtet über die -2-
finanztreff.de - May 6 at 3:36 AM
Morphosys: Umsatzrückgang fällt geringer aus als erwartetMorphosys: Umsatzrückgang fällt geringer aus als erwartet
onvista.de - May 6 at 3:36 AM
Morphosys schreibt Verlust und bestätigt PrognoseMorphosys schreibt Verlust und bestätigt Prognose
finanztreff.de - May 6 at 3:36 AM
Morphosys mit weniger Umsatzrückgang als erwartetMorphosys mit weniger Umsatzrückgang als erwartet
msn.com - May 6 at 3:36 AM
MorphoSys-Aktie unter Druck: MorphoSys schreibt VerlustMorphoSys-Aktie unter Druck: MorphoSys schreibt Verlust
finanzen.net - May 6 at 3:36 AM
Morphosys AG (spons. ADRs) hosts conference call for investorsMorphosys AG (spons. ADRs) hosts conference call for investors
markets.businessinsider.com - May 5 at 7:08 PM
MorphoSys (NASDAQ:MOR) Hits New 1-Year Low at $21.25MorphoSys (NASDAQ:MOR) Hits New 1-Year Low at $21.25
americanbankingnews.com - May 5 at 12:05 PM
Incyte Corp (INCY) Q1 2021 Earnings Call TranscriptIncyte Corp (INCY) Q1 2021 Earnings Call Transcript
msn.com - May 4 at 1:16 PM
Heres what Wall Street expects from MorphoSyss earningsHere's what Wall Street expects from MorphoSys's earnings
markets.businessinsider.com - May 4 at 7:58 AM
MorphoSys AG (NASDAQ:MOR) Sees Large Growth in Short InterestMorphoSys AG (NASDAQ:MOR) Sees Large Growth in Short Interest
americanbankingnews.com - May 3 at 2:58 PM
DGAP-PVR: MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten VerbreitungDGAP-PVR: MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
boersennews.de - May 1 at 3:55 PM
Biotech Report Biontech (22UA) und MorphoSys (MOR) sehr festBiotech Report Biontech (22UA) und MorphoSys (MOR) sehr fest
wallstreet-online.de - April 30 at 12:48 PM
Anlegerverlag Rückenwind bei MorphoSys!Anlegerverlag Rückenwind bei MorphoSys!
wallstreet-online.de - April 30 at 12:48 PM
DateCompanyBrokerageAction
4/27/2021ArvinasTruist SecuritiesInitiated Coverage
4/21/2021ArvinasNorthern Trust Capital MarketsInitiated Coverage
3/31/2021ArvinasBMO Capital MarketsInitiated Coverage
3/30/2021ArvinasCantor FitzgeraldBoost Price Target
1/19/2021ArvinasOppenheimerBoost Price Target
12/21/2020ArvinasPiper SandlerBoost Price Target
12/15/2020ArvinasCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/15/2020ArvinasSmith Barney CitigroupBoost Price Target
12/15/2020ArvinasRoth CapitalBoost Price Target
12/14/2020ArvinasHC WainwrightReiterated Rating
12/14/2020ArvinasThe Goldman Sachs GroupBoost Price Target
12/14/2020ArvinasWedbushBoost Price Target
3/29/2021Karuna TherapeuticsBank of AmericaInitiated Coverage
3/4/2021Karuna TherapeuticsJMP SecuritiesBoost Price Target
3/4/2021Karuna TherapeuticsMizuhoBoost Price Target
2/26/2021Karuna TherapeuticsMaxim GroupReiterated Rating
2/9/2021Karuna TherapeuticsRoyal Bank of CanadaInitiated Coverage
1/5/2021Karuna TherapeuticsWilliam BlairReiterated Rating
6/3/2020Karuna TherapeuticsStifel NicolausBoost Price Target
5/11/2021Pacira BioSciencesNorthland SecuritiesLower Price Target
4/15/2021Pacira BioSciencesBerenberg BankInitiated Coverage
2/26/2021Pacira BioSciencesBarclaysBoost Price Target
1/21/2021Pacira BioSciencesSVB LeerinkDowngrade
1/8/2021Pacira BioSciencesNeedham & Company LLCBoost Price Target
9/30/2020Pacira BioSciencesJefferies Financial GroupBoost Price Target
10/7/2020AlkermesJPMorgan Chase & Co.Reiterated Rating
4/2/2020AlkermesMorgan StanleyLower Price Target
2/14/2020AlkermesCowenReiterated Rating
4/8/2021MorphoSysDeutsche Bank AktiengesellschaftReiterated Rating
5/12/2020MorphoSysHSBCUpgrade
11/27/2019MorphoSysGuggenheimInitiated Coverage
11/5/2018MorphoSysPiper Jaffray CompaniesInitiated Coverage
(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.